Park Hyen Joo, Lee Hyun-Jung, Lee Eun-Jin, Hwang Hye Jin, Shin Sang-Hee, Suh Myung-Eun, Kim Choonmi, Kim Hwa Jung, Seo Eun-Kyung, Lee Sang Kook
College of Pharmacy, Ewha Womans University, Seoul, Korea.
Biosci Biotechnol Biochem. 2003 Sep;67(9):1944-9. doi: 10.1271/bbb.67.1944.
A series of benz[f]indole-4,9-diones, based on the antitumor activity of 1,4-naphthoquinone, were synthesized and evaluated for their cytotoxic activity in cultured human cancer cell lines A549 (lung cancer), Col2 (colon cancer), and SNU-638 (stomach cancer), and also for the inhibition of human DNA topoisomerases I and II activity in vitro. Several compounds including 2-amino-3-ethoxycarbonyl-N-methyl-benz[f]indole-4,9-dione showed a potential cytotoxic activity judged by IC50<20.0 microg/ml in the panel of cancer cell lines. Especially, 2-hydroxy-3-ethoxycarbonyl-N-(3,4-dimethylphenyl)-benz[f]indole-4,9-dione had potential selective cytotoxicity against lung cancer cells (IC50=0.4 microg/ml)) compared to colon (IC50>20.0 microg/ml) and stomach (IC50>20.0 microg/ml) cancer cells. To further investigate the cytotoxic mechanism, the effects of test compounds on DNA topoisomerase I and II activities were used. In a topoisomerase I-mediated relaxation assay using human placenta DNA topoisomerase I and supercoiled pHOTI plasmid DNA, 2-amino-3-ethoxycarbonyl-N-(4-fluorophenyl)-benz[f]indole-4,9-dione had the most potent inhibitory activity among the compounds tested. However, most of the compounds showed only weak inhibition of the DNA topoisomerase II-mediated KDNA (Kinetoplast DNA) decatenation assay, except for 2-amino-3-ethoxycarbonyl-N-(4-methylphenyl)-benz[f]indole-4,9-dione and 2-amino-3-ethoxycarbonyl-N-(2-bromoehtyl)-benz[f]indole-4,9-dione with a moderate inhibitory activity. These results suggest that several active compounds had relatively selective inhibitory activity against toposiomearse I compared to toposiomerase II. No obvious correlation was observed between the cytotoxicity of the individual compound and the inhibitory activity of DNA relaxation and decatenation by topoisomerase I and II, respectively, in vitro.
基于1,4 - 萘醌的抗肿瘤活性,合成了一系列苯并[f]吲哚 - 4,9 - 二酮,并在培养的人癌细胞系A549(肺癌)、Col2(结肠癌)和SNU - 638(胃癌)中评估了它们的细胞毒性活性,还在体外评估了它们对人DNA拓扑异构酶I和II活性的抑制作用。包括2 - 氨基 - 3 - 乙氧羰基 - N - 甲基 - 苯并[f]吲哚 - 4,9 - 二酮在内的几种化合物在癌细胞系组中,根据IC50<20.0微克/毫升判断显示出潜在的细胞毒性活性。特别是,与结肠癌细胞(IC50>20.0微克/毫升)和胃癌细胞(IC50>20.0微克/毫升)相比,2 - 羟基 - 3 - 乙氧羰基 - N -(3,4 - 二甲基苯基) - 苯并[f]吲哚 - 4,9 - 二酮对肺癌细胞具有潜在的选择性细胞毒性(IC50 = 0.4微克/毫升)。为了进一步研究细胞毒性机制,研究了测试化合物对DNA拓扑异构酶I和II活性的影响。在使用人胎盘DNA拓扑异构酶I和超螺旋pHOTI质粒DNA的拓扑异构酶I介导的松弛试验中,2 - 氨基 - 3 - 乙氧羰基 - N -(4 - 氟苯基) - 苯并[f]吲哚 - 4,9 - 二酮在所测试的化合物中具有最有效的抑制活性。然而,除了具有中等抑制活性的2 - 氨基 - 3 - 乙氧羰基 - N -(4 - 甲基苯基) - 苯并[f]吲哚 - 4,9 - 二酮和2 - 氨基 - 3 - 乙氧羰基 - N -(2 - 溴乙基) - 苯并[f]吲哚 - 4,9 - 二酮外,大多数化合物在DNA拓扑异构酶II介导的KDNA(动质体DNA)解连环试验中仅表现出微弱的抑制作用。这些结果表明,与拓扑异构酶II相比,几种活性化合物对拓扑异构酶I具有相对选择性的抑制活性。在体外,未观察到单个化合物所具有的细胞毒性与拓扑异构酶I和II分别对DNA松弛和解连环的抑制活性之间存在明显的相关性。